ecancermedicalscience

Erratum

Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayeasian network meta-analysis

12 Oct 2021
Victor Hugo Fonseca de Jesus, Rachel P Riechelmann

Throughout the text, please consider that the primary outcome of the PRODIGE24 trial was disease-free survival, and not overall survival.

Related Articles

Pengkhun Nov, Yangfeng Zhang, Duanyu Wang, Syphanna Sou, Socheat Touch, Samnang Kouy, Virak Vicheth, Lilin Li, Xiang Liu, Changqian Wang, Peizan Ni, Qianzi Kou, Ying Li, Chongyang Zheng, Arzoo Prasai, Wen Fu, Wandan Li, Kunpeng Du, Jiqiang Li
Gustavo Hipólito Diaz Infantes, Edgar Fermín Yan Quiroz, Luis Fernando Meza Montoya, José Richard Tenazoa Villalobos
Francis Okongo, Catherine Amuge, Alfred Jatho, Nixon Niyonzima, David Martin Ogwang, Jackson Orem
Natalia Camejo, Camila Montenegro, Dahiana Amarillo, Cecilia Castillo, Gabriel Krygier